Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 4:15:1401000.
doi: 10.3389/fphar.2024.1401000. eCollection 2024.

The efficacy of stereotactic radiotherapy followed by bevacizumab and temozolomide in the treatment of recurrent glioblastoma: a case report

Wangyan Zhong  1 , Jiwei Mao  1 , Dongping Wu  1 , Jianghua Peng  2 , Wanli Ye  1
Affiliations
Case Reports

The efficacy of stereotactic radiotherapy followed by bevacizumab and temozolomide in the treatment of recurrent glioblastoma: a case report

Wangyan Zhong et al. Front Pharmacol. .

Abstract

Glioblastoma (GBM) is the most common and aggressive malignant brain tumor among adults. Despite advancements in multimodality therapy for GBM, the overall prognosis remains poor, with an extremely high risk of recurrence. Currently, there is no established consensus on the optimal treatment option for recurrent GBM, which may include reoperation, reirradiation, chemotherapy, or a combination of the above. Bevacizumab is considered a first-line treatment option for recurrent GBM, as is temozolomide. However, in recurrent GBM, it is necessary to balance the risks and benefits of reirradiation in combination with bevacizumab and temozolomide. Herein, we report the case of a patient with recurrent GBM after standard treatment who benefited from stereotactic radiotherapy followed by bevacizumab and temozolomide maintenance therapy. Following 16 months of concurrent chemoradiotherapy (CCRT), the patient was diagnosed with recurrent GBM by a 3-T contrast-enhanced magnetic resonance imaging (MRI). The addition of localized radiotherapy to the ongoing treatment regimen of bevacizumab, in combination with temozolomide therapy, prolonged the patient's disease-free survival to over 2 years, achieving a significant long-term outcome, with no notable adverse effects observed. This clinical case may provide a promising new option for patients with recurrent GBM.

Keywords: bevacizumab; combination therapy; recurrent glioblastoma; stereotactic radiotherapy; temozolomide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Diagnosis of Glioblastoma. Axial (A), coronal (B) and sagittal (C) Diagnostic imaging result. T1-weighted MRI demonstrating a contrast-rim-enhancing lesion of the right temporal lobe. (D) Hematoxylin and eosin stains of the tumor, showing vascular endothelial cell proliferation at 100x.
FIGURE 2
FIGURE 2
Timeline of treatment and radiographic responses. (A) Timeline of treatment. Abbreviations: Glioblastoma (GBM), partial response (PR), complete response (CR), bevacizumab (BEV), temozolomide (TMZ), stereotactic radiotherapy (SRT); (B, C) The post-contrast T1-weighted MRI showing regression of the lesion and demonstrating the effectiveness of SRT followed by bevacizumab (BEV) and temozolomide (TMZ).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ajlan A., Thomas P., Albakr A., Nagpal S., Recht L. (2017). Optimizing bevacizumab dosing in glioblastoma: less is more. J. Neurooncol 135 (1), 99–105. 10.1007/s11060-017-2553-2 - DOI - PubMed
    1. Ali A. S., Lombardo J., Niazi M. Z., Miller R. C., Alnahhas I., Martinez N. L., et al. (2022). Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study. J. Neuro-Oncology 160 (2), 345–350. 10.1007/s11060-022-04146-w - DOI - PubMed
    1. Alimohammadi E., Bagheri S. R., Taheri S., Dayani M., Abdi A. (2020). The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review. Oncol. Rev. 14 (1), 461. 10.4081/oncol.2020.461 - DOI - PMC - PubMed
    1. Baehr A., Trog D., Oertel M., Welsch S., Kröger K., Grauer O., et al. (2020). Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts. Strahlenther Onkol. 196 (5), 457–464. 10.1007/s00066-020-01585-0 - DOI - PubMed
    1. Balañá C., Etxaniz O., Bugés C., Martínez A. (2011). Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error? Clin. Transl. Oncol. 13 (3), 209–210. 10.1007/s12094-011-0642-9 - DOI - PubMed

Publication types

LinkOut - more resources